Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 50: 467-468, 2004; 10.1373/clinchem.2003.029744
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marsden, D.
Right arrow Articles by Larson, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marsden, D.
Right arrow Articles by Larson, C. A.
Related Collections
Right arrow Pediatric Clinical Chemistry
Right arrow Endocrinology and Metabolism
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2004;50:467-468.)
© 2004 American Association for Clinical Chemistry, Inc.


Editorial

Emerging Role for Tandem Mass Spectrometry in Detecting Congenital Adrenal Hyperplasia

Deborah Marsden1,a and Cecilia A. Larson2

1 Children’s Hospital Boston, Boston, MA 021152 New England Newborn Screening Program, Jamaica Plain, MA 02130

aAuthor for correspondence. Fax 617-730-0466; e-mail deborah.marsden@tch.harvard.edu.

The first 20% of the full text of this article appears below.

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders caused by a deficiency of one of five enzymes required for the synthesis of cortisol and aldosterone. The most common type of CAH is 21-hydroxylase deficiency (21OHD), which is attributable to mutations in the gene CYP21 and a pseudogene, CYP21P, located on the short arm of chromosome 6. As with other genetic disorders, genotype does not always predict phenotype.

The phenotypic spectrum associated with 21OHD ranges from asymptomatic to early onset (as early as the fourth day of life) of severe salt-wasting crisis characterized by hypotension and electrolyte abnormalities that, if uncorrected, lead to death. Increased androgenic steroids, attributable to accumulated precursors proximal to the enzyme defect, cause ambiguous genitalia in female infants, leading to earlier clinical evaluation in girls. Virilized infant boys, however, are not always recognized, and many will present with acute catastrophic symptoms. Approximately 70% of infants with classic 21OHD have the salt-wasting form.

All newborns in the US are offered medical screening that uses blood collected shortly after birth on filter-paper cards, but the disorders screened for vary from state to state. All US states screen for phenylketonuria (PKU) and congenital hypothyroidism, and 36 states screen for CAH (1). A filter-paper immunoassay to screen for CAH has been available since 1977 (2). This approach relies on measurement of 17-hydroxyprogesterone (17OHP), which is normally converted to 11-deoxycortisol by CYP21 . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
M. M. Kushnir, A. L. Rockwood, W. L. Roberts, E. G. Pattison, W. E. Owen, A. M. Bunker, and A. W. Meikle
Development and Performance Evaluation of a Tandem Mass Spectrometry Assay for 4 Adrenal Steroids
Clin. Chem., August 1, 2006; 52(8): 1559 - 1567.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
S. Kosel, S. Burggraf, R. Fingerhut, H. G. Dorr, A. A. Roscher, and B. Olgemoller
Rapid Second-Tier Molecular Genetic Analysis for Congenital Adrenal Hyperplasia Attributable to Steroid 21-Hydroxylase Deficiency
Clin. Chem., February 1, 2005; 51(2): 298 - 304.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
M. G. Forest
Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Hum. Reprod. Update, November 1, 2004; 10(6): 469 - 485.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.